| Expression pattern: |
UP |
| Associated gene: |
AGO2, EIF4A3, FUS, HIPK2 |
| Associated microRNA: |
- |
| Biological function: |
Potential plasma biomarker for diagnosing MDD and predicting response to antidepressive treatment; positively correlated with neuropsychological assessment scores in MDD patients; bioinformatically predicted to participate in MDD-related pathophysiological processes. |
| Molecular mechanism: |
Bioinformatics-predicted ceRNA mechanism, RNA-binding protein interaction, and parent gene-related biological processes; predicted pathways include p53 signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, TNF signaling pathway, Hippo signaling pathway and Ras signaling pathway. |
| Biological pathway or process: |
ceRNA regulation (other); p53 signaling (other); PI3K/AKT (other); AMPK (other); Hippo/YAP (other); inflammation (other); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis; Cohort Study |
| Clinical significance: |
circHIPK2 could serve as a potential biomarker for diagnosing MDD and predicting therapeutic effects of MDD; baseline circHIPK2 levels showed AUC 0.796 for MDD diagnosis, and the 14-day change rate showed AUC 0.819 for predicting antidepressive effects. |
| Description: |
The study reports that plasma circHIPK2/hsa_circ_0001756 is up-regulated in patients with major depressive disorder and correlates with several depression-related neuropsychological scores. It is proposed as a blood-based biomarker for MDD diagnosis and for predicting response to 14-day antidepressive treatment, while bioinformatics analyses suggest potential ceRNA, RBP-interaction, and host-gene-related mechanisms. |
| Confidence score: |
0.6023 |